Abstract:Introduction:Infants exposed to opioids in utero are at high risk of exhibiting Neonatal Opioid Withdrawal Syndrome (NOWS), a combination of somatic withdrawal symptoms including high pitched crying, sleeplessness, irritability, gastrointestinal distress, and in the worst cases, seizures. The heterogeneity of in utero opioid exposure, particularly exposure to polypharmacy, makes it difficult to investigate the underlying molecular mechanisms that could inform early diagnosis and treatment of NOWS, and challenging to investigate consequences later in life.Methods:To address these issues, we developed a mouse model of NOWS that includes gestational and post-natal morphine exposure that encompasses the developmental equivalent of all three human trimesters and assessed both behavior and transcriptome alterations.Results:Opioid exposure throughout all three human equivalent trimesters delayed developmental milestones and produced acute withdrawal phenotypes in mice reminiscent of those observed in infants. We also uncovered different patterns of gene expression depending on the duration and timing of opioid exposure (3-trimesters, in utero only, or the last trimester equivalent only). Opioid exposure and subsequent withdrawal affected social behavior and sleep in adulthood in a sex-dependent manner but did not affect adult behaviors related to anxiety, depression, or opioid response.Discussion:Despite marked withdrawal and delays in development, long-term deficits in behaviors typically associated with substance use disorders were modest. Remarkably, transcriptomic analysis revealed an enrichment for genes with altered expression in published datasets for Autism Spectrum Disorders, which correlate well with the deficits in social affiliation seen in our model. The number of differentially expressed genes between the NOWS and saline groups varied markedly based on exposure protocol and sex, but common pathways included synapse development, the GABAergic and myelin systems, and mitochondrial function.

Preimplantation mouse embryo is a target for opioid ligand-receptor signaling.

Systemic Morphine Treatment Derails Normal Uterine Receptivity, Leading to Embryo Implantation Failure in Mice

Spatiotemporal Expression of Endogenous Opioid Processing Enzymes in Mouse Uterus at Peri-Implantation

Molecular and Long-Term Behavioral Consequences of Neonatal Opioid Exposure and Withdrawal in Mice.

Towards Functional Annotation of the Preimplantation Transcriptome: an RNAi Screen in Mammalian Embryos.

Preconception opioids interact with mouse strain to alter morphine withdrawal in the next generation

Aberrant cannabinoid signaling impairs oviductal transport of embryos

Ovarian Stimulation Makes A Disruption of Imprinting Genes of Mouse Oocyte and Placenta.

Early developing embryos affect the gene expression patterns in the mouse oviduct.

The effects of buprenorphine and morphine during pregnancy: Impact of exposure length on maternal brain, behavior, and offspring neurodevelopment

Effect of ubiquitin-proteasome pathway on mouse blastocyst implantation and expression of matrix metalloproteinases-2 and -9

Uterine Micro-Environment and Estrogen-Dependent Regulation of Osteopontin Expression in Mouse Blastocyst

Buprenorphine Induces Human Fetal Membrane Sterile Inflammation

Advances in animal models of prenatal opioid exposure

Effect of Prenatal Opioid Exposure on the Human Placental Methylome

Efficient delivery of DNA and morpholinos into mouse preimplantation embryos by electroporation

Decreased myelin-related gene expression in the nucleus accumbens during spontaneous neonatal opioid withdrawal in the absence of long-term behavioral effects in adult outbred CFW mice

Reproductive and developmental toxicity assessments of LPM3480392, a novel mu opioid receptor biased agonist in rats

Abnormal Morphology and Synaptogenic Signaling in Astrocytes Following Prenatal Opioid Exposure

Differential regulation of endocannabinoid synthesis and degradation in the uterus during embryo implantation.